JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1989; 14:1326-1330
© 1989 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ravid, S
Right arrow Articles by Lown, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ravid, S
Right arrow Articles by Lown, B

Congestive heart failure induced by six of the newer antiarrhythmic drugs

S Ravid, PJ Podrid, S Lampert, and B Lown

Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts.

The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests. The incidence rate ranged from 0.7% with lorcainide to 4.7% with propafenone. Congestive heart failure was present in 167 patients (41%) who underwent 491 drug trials. Congestive failure was induced in 15 (9%) of these 167 patients and involved 19 (3.9%) of the 491 tests. Left ventricular ejection fraction was 20 +/- 8% in patients who developed congestive failure, in contrast to 39 +/- 19% in those who did not (p less than 0.001). It is concluded that each of the six antiarrhythmic drugs examined has the potential to aggravate congestive heart failure in patients with reduced left ventricular ejection fraction or a history of congestive heart failure, but the incidence rate is low and its occurrence unpredictable.


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
I. A. Khan
Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation
J. Am. Coll. Cardiol., February 1, 2001; 37(2): 542 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. O. Peralta, R. M. John, W. H. Gaasch, P. I. Taggart, D. T. Martin, and F. J. Venditti
The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart
J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1404 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Cice, E. Tagliamonte, L. Ferrara, and A. Iacono
Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study
Eur. Heart J., August 1, 2000; 21(15): 1259 - 1264.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
A.U Khand, A.C Rankin, G.C Kaye, and J.G.F Cleland
Systematic review of the management of atrial fibrillation in patients with heart failure
Eur. Heart J., April 2, 2000; 21(8): 614 - 632.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. L. Yong, R. Xu, J. G. McLarnon, A. B. Zolotoy, G. N. Beatch, and M. J. A. Walker
RSD1000: A Novel Antiarrhythmic Agent with Increased Potency under Acidic and High-Potassium Conditions
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 236 - 244.
[Abstract] [Full Text]

Home page
 J CARDIOVASC PHARMACOL THERHome page
A. Serdar Fak, H. Tezcan, O. Caymaz, S. Tokay, S. Oktay, and A. Oktay
Intravenous Propafenone for Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm: A Randomized, Placebo-controlled, Crossover Study
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 251 - 257.
[Abstract] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1989 by the American College of Cardiology Foundation.